Skip to main content

Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.

Publication ,  Journal Article
Iguchi, T; Kimura, G; Fukasawa, S; Suzuki, H; Uemura, H; Nishimura, K; Matsumoto, H; Yokomizo, A; Armstrong, AJ; Rosbrook, B; Sugg, J; Chen, L ...
Published in: Int J Urol
July 2021

OBJECTIVE: To evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer. METHODS: A post-hoc analysis of the Japanese subgroup in the phase III, randomized, multinational ARCHES study (NCT02677896) was carried out. Patients with metastatic hormone-sensitive prostate cancer were randomized to receive enzalutamide or a placebo, plus androgen deprivation therapy, stratified by disease volume and prior docetaxel therapy. The primary end-point was radiographic progression-free survival. Secondary end-points included time to prostate-specific antigen progression and overall survival. RESULTS: Of 1150 patients, 92 Japanese patients were randomized to enzalutamide (n = 36) or a placebo (n = 56), plus androgen deprivation therapy; none received prior docetaxel. Enzalutamide plus androgen deprivation therapy reduced the risk of radiographic progression or death in Japanese patients by 61% versus the placebo, similar to the overall population. Similar results were observed with secondary end-points, showing clinical benefit of enzalutamide plus androgen deprivation therapy in Japanese patients. Overall survival data were immature. Grade 3-4 adverse events were reported in 47% and 25% of the enzalutamide and placebo groups, respectively. Nasopharyngitis, hypertension and abnormal hepatic function were reported more frequently in Japanese patients versus the overall population. CONCLUSIONS: Enzalutamide plus androgen deprivation therapy has clinical benefit with a tolerable safety profile in Japanese men with metastatic hormone-sensitive prostate cancer, consistent with the overall population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Urol

DOI

EISSN

1442-2042

Publication Date

July 2021

Volume

28

Issue

7

Start / End Page

765 / 773

Location

Australia

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Prostatic Neoplasms, Castration-Resistant
  • Phenylthiohydantoin
  • Nitriles
  • Male
  • Japan
  • Humans
  • Benzamides
  • Androgens
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Iguchi, T., Kimura, G., Fukasawa, S., Suzuki, H., Uemura, H., Nishimura, K., … Stenzl, A. (2021). Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. Int J Urol, 28(7), 765–773. https://doi.org/10.1111/iju.14568
Iguchi, Taro, Go Kimura, Satoshi Fukasawa, Hiroyoshi Suzuki, Hiroji Uemura, Kazuo Nishimura, Hiroaki Matsumoto, et al. “Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.Int J Urol 28, no. 7 (July 2021): 765–73. https://doi.org/10.1111/iju.14568.
Iguchi, Taro, et al. “Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.Int J Urol, vol. 28, no. 7, July 2021, pp. 765–73. Pubmed, doi:10.1111/iju.14568.
Iguchi T, Kimura G, Fukasawa S, Suzuki H, Uemura H, Nishimura K, Matsumoto H, Yokomizo A, Armstrong AJ, Rosbrook B, Sugg J, Baron B, Chen L, Kunieda F, Stenzl A. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. Int J Urol. 2021 Jul;28(7):765–773.

Published In

Int J Urol

DOI

EISSN

1442-2042

Publication Date

July 2021

Volume

28

Issue

7

Start / End Page

765 / 773

Location

Australia

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Prostatic Neoplasms, Castration-Resistant
  • Phenylthiohydantoin
  • Nitriles
  • Male
  • Japan
  • Humans
  • Benzamides
  • Androgens